Appu Rathinavelu, Ph.D.
Executive Director, Rumbaugh-Goodwin Institute for Cancer Research
Discovering New Cancer Therapies
Appu Rathinavelu, Ph.D. has been involved in cancer research since 1992, and under his leadership as Executive Director, NSU’s Rumbaugh-Goodwin Institute for Cancer Research, is conducting groundbreaking research on new cancer therapeutics and powerful diagnostic methods for breast, lung, pancreatic and colorectal cancers. Rathinavelu’s work also includes identification of gene defects and cellular mechanisms that enhance cancer spreading and drug resistance.
Rathinavelu, who has two pending patents for breast cancer therapeutics and a synthetic chemical, is developing novel cancer drugs through pharmacogenomics and molecular modeling approaches. His synthetic chemical is projected to severely limit or stop the growth of blood vessel formation in cancerous tissues.
He has published more than 30 peer-reviewed research articles, served as reviewer for scientific publications, co-authored a text book and given more than 75 presentations at national and international conferences. He was member of the Center of Excellence for Marine Biology and Biotechnology and is currently a member of the Bioinformatics Consortium that involves Nova Southeastern University and Florida Atlantic University scientists.
Rathinavelu received his Ph.D. in biochemistry from the University of Madras and conducted his postdoctoral training at Purdue University. In 1992, he joined the Department of Pharmaceutical Sciences at Southeastern University’s College of Pharmacy, and he is currently chairman of the Department of Pharmaceutical and Administrative Sciences at NSU’s College of Pharmacy.